Purpose. To evaluate the Luminex NxTAG respiratory pathogen panel (NxTAG RPP) for the detection of respiratory viruses in clinical samples from patients with the symptoms of respiratory infection.
INTRODUCTION
A wide range of viruses and bacteria can be the aetiological agent of respiratory tract infections (RTIs) in humans, and can cause illnesses that range from upper respiratory tract symptoms through to severe acute respiratory distress and pneumonia. Diagnosis of the aetiological agent based on symptoms alone is problematic because a wide range of pathogens can be associated with similar clinical presentation [1] . The rapid and accurate identification of the aetiological cause of RTIs is important for the management and treatment of the patient, and for infection control purposes [2] . Viral culture, often in association with immunofluorescence assays, has been used for the identification of viral respiratory pathogens for many years, but these methods lack sensitivity, and culture in particular is slow and lacks specificity. The development of nucleic acid amplification tests (NATs) has significantly improved the detection of respiratory viruses and has become the gold standard for the identification of pathogenic viruses in patient samples because of its high sensitivity and specificity [2] .
In the absence of commercially available NATs for respiratory virus testing, many laboratories developed in-house or laboratory-developed NAT tests (LDTs), with several published assay protocols becoming widely adopted by many clinical diagnostic laboratories [3] . Although in recent years commercial tests have become available, many laboratories have not adopted them for reasons such as relative cost in comparison to LDTs, lack of peer-reviewed comparative data for assay performance and local laboratory accreditation issues [3] . Prior to them being adopted, laboratories have to verify their performance against existing tests and consider the advantages and potential limitations they present. The Luminex NxTAG respiratory pathogen panel (NxTAG RPP) is a qualitative NAT for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs, bronchoalveolar lavages (BALs), nasal and tracheal aspirates, nasal washes, sputum and throat swabs collected from individuals with clinical signs and symptoms of respiratory infection [4] . The pathogens included in the panel include adenovirus; human bocavirus; human coronavirus 229E, NL63, OC43 and HKU1; rhinovirus/enterovirus (hRV/Ent); influenza A virus H3 and H1N1; influenza B virus; human metapneumovirus; parainfluenza virus 1, 2, 3 and 4 (PIV 1-4); respiratory syncytial virus A and B (RSV); Chlamydophila pneumoniae; Mycoplasma pneumoniae; and Legionella pneumophila. The performance of the NxTAG RPP assay has previously been compared to that of a range of other commercial assays, including the Luminex xTAG respiratory panel (xTAG RVP) FAST v2 [5, 6] , the FilmArray RP test [4, 7] , the Seegene Anyplex II RV16 assay [8] and the RespiFinder panel [9] . There have been limited reports on the performance of the NxTAG RPP in comparison to LDTs. The performance of the NxTAG RPP has been compared to that of the FilmArray RP test plus in-house LDTs for bocavirus and L. pneumophila [7] . The performance of the NxTAG RPP has also been compared to that of the xTAG RVP and in-house LDTs for RSV A and B, metapneumovirus, hRV/Ent, adenovirus and M. pneumoniae [5] . In this study we compared the performance of the NxTAG RPP against that of in-house real-time PCR multiplex panel (LDT) based on widely adopted peer-reviewed protocols, which detects adenovirus, influenza A virus H3 and H1N1, influenza B virus, human metapneumovirus, PIV 1-4, RSV A and B, and rhinovirus, plus individual LDTs for human bocavirus, human coronavirus 229E, NL63, OC43 and HKU1, and enterovirus.
METHODS Samples
A total of 314 clinical samples were used in the study, and these included BALs (n=17), bronchial secretions (n=1), endotracheal secretions (n=47), eye swabs (n=1), nasal swabs (n=8), nasopharyngeal secretions (n=122), combined nose and throat swabs (n=41), sputum (n=24) and throat swabs (n=53). The samples were taken from symptomatic patients either on presentation at their GP surgery or in hospital between October 2014 and February 2016. Samples were initially tested in the LDT and were then stored at À80 C prior to testing in the NxTAG RPP assay. The 314 samples used in the study were selected based on the results of the LDT assay to ensure that the number of virus-positive samples would be higher than in randomly selected prospectively collected samples. In addition five Quality Control in Molecular Diagnostics (QCMD, Glasgow, UK) external quality assurance (EQA) panels were tested in the NxTAG RPP and LDT tests with the human rhinovirus (2014 and 2015), human metapneumovirus (2014), parainfluenza virus (2014) and adenovirus (2014) panels.
Nucleic acid extraction for LDT Total nucleic acid extraction was performed using a NucliS-ENS easyMAG system (bioMerieux, France) according to the manufacturer's instructions. In brief, 20 µl of brome mosaic virus (BMV) internal control was added to the 2 ml external lysis buffer and 200 µl of clinical sample added to the tube and mixed using a vortex mixer. It was then extracted using the generic (2.0.1) protocol with an elution volume of 55 µl.
Nucleic acid extraction for NxTAG RPP Following thawing of the samples after removal from storage at À80 C, total nucleic acid extraction was performed on the NucliSENS easyMAG system (bioMerieux, France) according to the manufacturer's instructions (generic protocol 2.0.1) with the following modifications. In brief, 10 µl of MS-2 internal control was substituted for the BMV internal control and the elution volume was changed to 110 µl.
In-house multiplex RT-PCR (LDT)
The nucleic acid extracts from the patient samples were tested in an in-house multiplex real-time PCR test (LDT) that targeted adenovirus, influenza A H3 virus, influenza A H1 virus (seasonal) and influenza A H1N1 2009 virus, influenza B virus, human metapneumovirus, PIV 1, 2, 3 and 4, RSV A and B, and rhinovirus, and individual LDTs for human bocavirus, human coronavirus 229E, NL63, OC43, HKU1 and enterovirus [10] [11] [12] [13] [14] . The amplification and detection were carried out on a TaqMan 7500 fast real-time PCR instrument (Life Technologies, UK) using TaqMan hydrolysis probes. The NxTAG RPP assay does not differentiate between enterovirus and rhinovirus, so the results of the LDT were pooled for the analysis.
Luminex NxTAG RPP
The NxTAG RPP test was performed as described in the manufacturer's instructions. Briefly, nucleic acid extracts or controls (35 µl) were added directly to the microtube containing the lyophilized reagents by piercing through the foil seal with a pipette tip. Following the sample addition, the wells were resealed using the provided metal foil seal. Then the microtube strips were transferred to the thermal cycler and the multiplexed reverse transcription PCR and hybridization reaction were carried out in a single cycling programme. Following amplification and hybridization, the microtube strips were immediately transferred to the MAG-PIX instrument for data acquisition and analysis. Data analysis and positive and negative analyte calls for the target pathogens were performed using SYNCT software.
Sequencing of samples with discordant results
Discordant results were resolved by direct sequencing of specific pathogen gene targets with PCR and Sanger sequencing primers designed not to overlap with the primers used in the NxTAG RPP assay. Dye-labelled terminator cycle sequencing was performed using a BigDye Terminator v 3.1 cycle sequencing kit (Thermo-Fisher, Waltham, MA, USA), with sample electrophoresis and sequence analysis performed on a 3730xl analyzer (Thermo-Fisher) using 3730xl data collection software (v 3.1.1) and sequencing analysis software (v 5.4). Sequences that were at least 200 bases in length were further analysed using NCBI BLAST searches.
Statistical analysis
In the absence of a reference standard, the performance of the NxTAG RPP and LDT tests was assessed by calculating the overall percentage agreement (OPA), the positive percentage agreement (PPA) and the negative percentage agreement (NPA) as described previously [15] . The agreement between the two tests was assessed by calculating the Kappa coefficient if the total number of positives was equal to 20 or more using the method described previously [16] . Kappa values from 0.21 to 0.4 represent fair agreement; those from 0.41 to 0.6 represent moderate agreement; and those from 0.61 to 0.8 and 0.81 to 0.99 indicate substantial and almost perfect agreement, respectively. The confidence intervals (CI) were set at 95 % for the OPA and Kappa coefficient calculations, but CIs were not calculated for PPA and OPA because imperfect standard results are subject to variability and the nature of variability depends on unknown factors [15] .
RESULTS
Of the 314 samples tested, 2 were invalid in the NxTAG RPP assay and were therefore excluded from the final analysis. Of the 312 other samples, 31 were negative in both tests, with 193 samples having a single virus present that was concordantly detected by both tests (Table 1) . Fourteen samples had a single pathogen detected in them with discordant results between the two tests. Eleven of the 14 samples were positive in the NxTAG RPP test but negative in the LDT, 1 sample was positive for influenza A H3 in the LDT and negative in the NxTAG RPP, and 2 samples were positive for adenovirus in the LDT but positive for hRV/Ent and NL63, respectively, in the NxTAG RPP test. Multiple infections were detected in 74 samples, with 42 samples having 2 viruses present, with the results being concordant in both tests, and 2 samples having 3 viruses present, again concordantly detected by both tests. Overall a total of 268 samples had concordant results in both tests.
Overall, a total of 367 viruses were detected in the samples, of which 316 were detected concordantly in both tests. Thirty samples had multiple viruses detected in them, with the results being discordant between the two tests. Of the 51 viruses detected discordantly between the 2 tests, 5 viruses were detected by the LDT but were negative in the NxTAG RPP, and 46 were positive in the NxTAG RPP and negative in the LDT, with hRV/Ent being the most frequently discordantly detected pathogen (n=12). Twenty-six samples had insufficient sample volume left to send for bi-directional sequencing (Table 2) . Of the remaining 25 sent for sequencing, 23 (92 %) were confirmed as being correctly positive for the virus detected in the NxTAG RPP test.
hRv/Ent was the most commonly detected pathogen (n=106, 33.7 %), followed by RSV A (n=52, 16.6 %), adenovirus (n=48, 15.3 %), PIV 3 (n=42, 13.4 %), influenza A (n=40, 12.7 %) and metapneumovirus (n=30, 9.6 %). The overall agreement between the two assays was relatively high, with OPA values ranging from 96.2 % for enterovirus/ rhinovirus up to 100.0 % for influenza A H1, influenza B, PIV 4 and RSV B. The PPA value was 90.0% for adenovirus, 97.4 % for influenza A H3 and 100 % for the other targets, except PIV 2, because the PPA could not be calculated in the absence of any positives. The NPA values ranged from 94.5 % for hRV/Ent up to 100 % for influenza A H3, influenza H1N1, influenza B, PIV 4 and RSV B. The Kappa coefficients were calculated for pathogens for which there were 20 or more positives, and the values ranged from 0.85 for metapneumovirus to 0.91 for adenovirus, hRV/Ent and parainfluenza 3, 0.95 for influenza A H3 and 0.96 for RSV A, indicating an almost perfect agreement between the 2 assays for these target pathogens. Positive predictive values (PPV) and negative predictive values (NPV) were not calculated because of sample bias in the patient population caused by mainly selecting samples that had previously been demonstrated to be positive in the LDT.
Five EQA panels from QCMD were also tested in both assays ( Table 3 
DISCUSSION
The performance of the NxTAG RPP has previously been compared to that of other commercially available multiplex tests for respiratory pathogens. However, this is the first study to compare the performance of the NxTAG RPP to that of a comprehensive multiplex LDT based on widely adopted peer-reviewed protocols for the detection of viral pathogens in respiratory samples collected from individuals with clinical signs and symptoms of respiratory infection. In this study the overall agreement between the NxTAG RPP and the LDT was very high, as demonstrated by the Kappa coefficients and the PPA and NPA values. A previous study [5] found the NxTAG RPP to be less sensitive and specific than singleplex real-time PCR assays, but we found the NxTAG RPP to be as sensitive as the LDTs for the majority of the target viruses detected. The previous study also noted a reduced sensitivity of detection for adenovirus using the NxTAG RPP [5] , which we also noted in our study, with four adenovirus-positive samples in the LDT being negative in the NxTAG RPP, but all four samples had relatively high Ct values of 36 cycles or above, indicating that they were at the lower limit of detection in the LDT. The NxTAG assay also failed to detect three adenovirus-positive samples in the adenovirus QCMD EQA panel, indicating that the sensitivity of detection of adenovirus in the NxTAG RPP assay was lower in this study compared to that of the LDT.
In many of the previous studies the performance of the NxTAG RPP was compared to that of the assay currently in use in the laboratory, with the authors assuming that the result from the currently used assay was the 'gold standard' against which the NxTAG assay's result should be compared. In this study we chose to evaluate the agreement between the two assays by calculating the Kappa coefficients and the PPA and NPA values, which provide more meaningful data in the absence of a gold standard. Unfortunately, of the 51 samples with discordant results, only 25 had sufficient sample left following testing in the NxTAG RPP for confirmation using sequencing, but of those 25, 23 were confirmed, indicating that for some targets the NxTAG RPP may be more sensitive than the LDT. In a previous study [7] polymicrobial infection was identified as being common, with >20 % cases being infected with two or more pathogens. In this study polymicrobial infections were identified in 74 (24 %) samples, demonstrating that this is a common phenomenon, and the usefulness of the syndromic multiplex approach to testing. The NxTAG RPP was applied to the detection of pathogens in a panel of 12 EQA samples in a previous study [6] . In this study we applied the NxTAG RPP assay to the detection of pathogens in 5 EQA panels (48 samples) from QCMD and demonstrated that the NxTAG RPP was more sensitive than the LDT for rhinovirus, PIV and metapneumovirus compared to the LDT. However, as noted above, the sensitivity of detection of adenovirus in the panels was lower when using the NxTAG RPP.
We acknowledge that this study has a number of limitations, including the low number of negative samples in the dataset and the inability to calculate PPV and NPV accurately because of the bias in the selection of samples from including large numbers of samples previously demonstrated to be positive for viral pathogens. Also, the fact that this was a retrospective study meant that samples had been stored for up to 12 months prior to thawing and retesting in the NxTAG RPP. This process may have had a deleterious effect on the quality of the nucleic acid extracts prior to testing in the NxTAG assay. As in previous studies [5, 6, 8] , we suffered from a low prevalence of some of the target pathogens, for example bocavirus, coronavirus NL63, 229E, PIV 1 and PIV 2, RSV B and influenza B, and a complete absence of others, including PIV 2, C. pneumoniae, M. pneumoniae and L. pneumophila, which prevented us from assessing the sensitivity of detection of these pathogens in the LDT and NxTAG RPP. In addition, our laboratory does not perform real-time PCR assays for the three bacterial targets, so we would have been unable to confirm any positives detected by the NxTAG RPP. The NxTAG RPP has a number of advantages compared to the LDT. Firstly, it has reduced 'hands-on time' and the process involves fewer steps compared with the LDT, making it a much more streamlined workflow, and although the assay has a slightly longer overall run time, this can be mitigated by having a slightly earlier assay start, which fits with the daily laboratory work flow. It also removes the need to maintain and quality-control large stocks of primers, probes and PCR enzymes. The NxTAG RPP is also CE-marked and approved as an IVD, which complies with laboratory accreditation authorities. The streamlined workflow and single well per test also allows the laboratory to increase throughput easily during periods of increased respiratory infection, something which is more difficult with the LDT, with its multiple wells per sample. The NxTAG RPP result interpretation via SYNCT software also avoids the subjectivity associated with interpreting real-time PCR fluorescent dye data.
The NxTAG RPP has a number of limitations compared to the LDT, including the lack of a Ct value, which may be a disadvantage when trying to interpret the significance of individual pathogens in polymicrobial infections. A previous study assessed the Luminex xTAG RVP as a semiquantitative screening assay for influenza virus detection using mean fluorescence intensity (MFI) to estimate virus concentration [17] . This concluded that the RVP kit has utility as a semi-quantitative assessment tool for the detection of influenza A and B virus in environmental samples, but did not demonstrate whether such an approach is applicable to the detection of the target pathogens in clinical samples. The inability of the NxTAG RPP to differentiate between enterovirus and rhinovirus infections may be of significance in complex or immunocompromised patients, and in those with non-respiratory symptoms such as meningitis; it also limits the information available for surveillance purposes. The adoption of a commercially produced assay always has the limitation that the user does not know the target sequences of the assay and so cannot monitor whether genetic variants arise, which may compromise the detection of pathogens in the assay. In addition, the adoption of a commercial assay may compromise the ability of the laboratory to respond to a newly emerged virus, such as a new influenza A virus variant, or a new coronavirus, such as SARS or MERS-CoV. Finally, the NxTAG RPP requires the manipulation of PCR products within the MAGPIX instrument, with the inherent risk of cross-contamination, which may result in false positive results in the assay. Overall, the NxTAG RPP is a sensitive, specific assay for the detection of respiratory pathogens, but it would be beneficial to evaluate its utility further using samples that are positive for the pathogens with lower incidence.
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